Complement Therapeutics
Developing the next generation of complement medicines
36 employees · est. 2020 · Germany
Rallybio
Unimagined therapies. Undreamed outcomes.
39 employees · est. 2018 · New Haven, United States
Rallybio is the older company (2020 vs 2018).
Side-by-Side Comparison
| Metric | Complement Therapeutics | Rallybio |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2018 older |
| Headquarters | ||
| Headquarters | Germany | New Haven, United States |
| Employees | ||
| Employees | 36 | 39 |
| Industry | ||
| Industry | Biotechnology | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series A | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $77.00M | $238.60M |
| Funding Rounds | ||
| Funding Rounds | 3 | 5 |
| Services | ||
| Services | Research and development of complement-related disease therapies, Development of gene and protein-based therapeutic platforms, Mass spectrometry for complement protein measurement | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with complement-mediated diseases, Individuals with age-related macular degeneration, Healthcare providers specializing in ocular and systemic diseases | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Complement-Mediated Diseases, Gene Therapy, Geographic Atrophy, Dry Age-Related Macular Degeneration, Precision Medicine, Diagnostic Platform, Vision Loss, Retinal Diseases, Complement Cascade, Preclinical Research, Patient Stratification, Efficacy Biomarker, Therapeutic Development | Clinical-stage, Therapies, Rare Diseases, Maternal Fetal Health, Complement Dysregulation, Hematology, Metabolic Disorders, Anti-HPA-1a Antibody, Fetal And Neonatal Alloimmune Thrombocytopenia, Complement Component 5 Inhibitor, University Of Connecticut, Technology Incubation Program, New Haven, Connecticut |
| Website | ||
| Website | complementtx.com | rallybio.com |
About Complement Therapeutics
Complement Therapeutics, founded in 2020, is a biotechnology company dedicated to pioneering the development of the next generation of complement medicines. Headquartered in Germany, this spinout from the University of Manchester focuses on innovative therapeutics for complement-mediated diseases....
About Rallybio
Rallybio is a clinical-stage biotechnology company, listed on NASDAQ as RLYB, focused on developing life-transforming therapies for severe and rare diseases. With a strong pipeline targeting maternal fetal health, complement dysregulation, hematology, and metabolic disorders, they have two clinical...
We will tell you when either one moves
BounceWatch watches Complement Therapeutics and Rallybio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Complement Therapeutic... and Rallybio — by email.
Frequently Asked Questions
Compare Complement Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Complement Therapeutics on 28 Jan 2026, and Rallybio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
